SHANGHAI, January 2, 2024 /PRNewswire/ -- Maiwei Biotech (688062.SH), an innovative biopharmaceutical company with a full industrial chain, announced that the company's R&D president Dr. Wu Hai will attend the 42nd J.P. Morgan Healthcare Annual Conference held in San Francisco, USA, and delivered a speech at the Biotech Showcase held at the same time on Maiwei Biotech's global cooperation strategy, innovative drug pipelines in the fields of oncology, autoimmunity and central nervous system, and IDDC ADC innovation technology platform. The accompanying R&D and business development team will conduct in-depth exchanges and discussions with global multinational pharmaceutical companies and biotech companies to accelerate the pace of expanding global partners.
About J.P. Morgan Healthcare Annual Meeting
J.P. Morgan Healthcare Conference (J.P. Morgan Healthcare Conference) is the largest and most informative healthcare conference in the world. It gathers executives and healthcare investors from major multinational companies and biotech SMEs to participate, leading the development and investment trends of the global healthcare industry.
regarding Biotech Showcase
Biotech Showcase attracts investors, biopharmaceutical executives, and experts from various fields in the industry from around the world, and is committed to providing collaboration opportunities for biotech and life sciences companies.
About Maiwei Biotech
Maiwei Biology (688062.SH) is an innovative biopharmaceutical company with a full industrial chain layout. It always adheres to the vision of “turning innovation from dream to reality” and carries out the mission of “exploring life and benefiting health”. Through innovation at the source, it provides patients with bioinnovative drugs with better curative efficacy and greater accessibility to meet unmet global clinical needs. Since its establishment in 2017, Maiwei Biotech has built an innovative system that covers the entire drug development cycle, including pharmacogenicity research, pre-clinical research, clinical research and production transformation, starting with antibody drug target discovery and molecular discovery, and has achieved a full industry chain layout integrating R&D, production and marketing. We focus on cancer and age-related diseases, covering treatment fields such as oncology, autoimmunity, metabolism, ophthalmology, infection, etc., and have established a rich and competitive pipeline with internationally leading specialty technology platforms and R&D innovation capabilities. Currently, 14 varieties are at various stages, including 10 innovative varieties and 4 biosimilar drugs. Of these, 2 varieties have been marketed, 2 drug marketing license applications have been accepted, and 3 varieties are in the critical registration clinical trial stage. It also independently undertakes 1 major national “major new drug creation” science and technology project, 2 national key research and development plans, and several provincial and municipal science and technology innovation projects. Maiwei Biotech is innovation-based and focuses on industrial transformation. The industrialization base for antibodies and recombinant protein drugs that meet China's NMPA, US FDA, and EU EMA GMP standards has been put into use in Taizhou, Jiangsu, and has passed the EU QP audit. Large-scale commercial production bases in Jinshan, Shanghai and Taizhou, Jiangsu are under construction. For more information, visit:.
Forward-looking statements
The information published in this press release may include certain forward-looking statements. These statements are inherently risky and uncertain. When using “anticipate”, “believe”, “anticipate”, “expect”, “intention” and other similar terms, the purpose of any statement relating to the Company is to indicate that it is a forward-looking statement. The Company is under no obligation to update these predictive statements on an ongoing basis.
These forward-looking statements are based on the Company's management's current views, assumptions, expectations, estimates, predictions, and understandings of future matters at the time of making the statements. These statements are not a guarantee of future development and are subject to risk, uncertainty and other factors. Some are beyond our control and difficult to predict. Therefore, due to future changes and developments in our business, competitive environment, political, economic, legal and social circumstances, actual results may differ materially from the information contained in the forward-looking statements.
The Company, its directors and employee agents are not responsible for (a) any obligation to correct or update the forward-looking statements contained on this website; and (b) any liability arising from the failure or inaccuracy of any forward-looking statements.